Product Highlight - Vyzulta

Breakthrough in Glaucoma Treatment Over 20 Years.

One Molecule, Two Outflow Pathways.

- Lowers IOP by increasing outflow through both the trabecular meshwork and uveoscleral pathway¹
- Greater mean diurnal IOP reduction from baseline vs Latanoprost 0.005%²
- Superior IOP reduction vs Timolol 0.5% at all tested time points³
- Demonstrated safety profile^3,4


Please refer to full package insert for the details.

References:
1. Cavet ME, DeCory HH. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies. J Ocul Pharmacol Ther 2018; 34(1-2): 52-60.
2. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99(6): 738-45.
3. Weinreb RN, Liebmann JM, Martin KR, et al. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. J Glaucoma 2018; 27(1): 7-15.
4. VYZULTA^® Hong Kong prescribing information [version: 06/2018].